Amarantus Bioscience Holdings Inc (AMBS)

[blackhawks]

Results of recent 'lunch meeting' deals of pharm companies that are presenting at The 15th Annual BIO CEO & Investor Conference.

AMBS is not a 'presenter'. Doesn't mean that they're not having lunch and laying down 'dots' with ....someone.

But this is what it looks like for companies that have signed deals, landed financial committments and secured FDA 'nods'. Maybe we're 'early' and AMBS will be on a similar list at next year's conference or, of course, maybe a deal will materialize much sooner.

2013 Presenting Company Highlights:

•Are Drugs for Ultra-Rare Diseases the Future of Biotech? NPS Weighs In
•Repligen, Pfizer Make $70M Spinal Muscular Atrophy Deal
•Alkermes Aims for Psychiatric Drug That Won’t Pack on the Pounds
•Regado Raises $51 Million in E Round
•Sutro, Celgene in Antibody Deal
•Sucampo Pharmaceuticals Wins FDA Approval for Glaucoma Treatment
•Oncolytics Soars on Early Peek at Phase III Study of Cancer Therapy
•$EXEL Grabs First FDA Nod for Blockbuster Hopeful Against Thyroid
•Acadia Surges on Parkinson's Psychosis Drug Study
•Rib-X Lands $67.5 Million To Advance Antibiotic Drug Research
•Alnylam Gets $22.5M from Genzyme for Asia Rights to Amyloidosis Drug

.

Didn't make the cut for a mention here:

http://www.thestreet.com/video/11835757/the-next-big-thing-in-biotech-bio-ceo-conference.html

The Next Big Thing In Biotech: BIO CEO Conference Adam Feuerstein, Sr. Columnist for TheStreet, says the BIO CEO Conference is the next big thing in biotech.

But maybe Mr. Feuerstein will stick around for Gerald's comments about AMBS and be as blown away by them, and with AMBS prospects, as many of us are who post here.